Results 1 to 10 of about 45,621 (284)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

Frontiers in Pharmacology, 2023
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted.
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Robert Rissmann, Robert Rissmann, Jesse J. Swen, Martijn L. Manson   +11 more
doaj   +2 more sources

PharmVar GeneFocus: CYP2C19 [PDF]

Clinical Pharmacology & Therapeutics, 2020
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues ...
M. R. Botton, Michelle Whirl‐Carrillo, Andria L. Del Tredici, K. Sangkuhl, L. Cavallari, J. Agúndez, J. Duconge, M. Lee, E. Woodahl, Karla Claudio‐Campos, A. Daly, T. Klein, V. Pratt, S. Scott, A. Gaedigk   +14 more
semanticscholar   +3 more sources

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study

BMC Cardiovascular Disorders, 2023
Background Genetic factors have a certain proportion in the risk factors of hypertension. The purpose was to investigate the relationship of cytochrome P450 2C19 (CYP2C19) polymorphisms with hypertension in Hakka population.
Nan Cai, Cunren Li, Xianfang Gu, Wenfeng Zeng, Jiawei Zhong, Jingfeng Liu, Guopeng Zeng, Junxing Zhu, Haifeng Hong   +8 more
doaj   +2 more sources

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse

Scientific Reports, 2021
CYP2C19*2 and CYP2C19*17 might influence tamoxifen metabolism and clinical outcome. Our aim was to investigate the effect of CYP2C19 genotypes on tamoxifen concentrations and metabolic ratios (MRs) and breast cancer recurrence in a large cohort of ...
A. B. Sanchez-Spitman, J. J. Swen, V. O. Dezentjé, D. J. A. R. Moes, H. Gelderblom, H. J. Guchelaar   +5 more
doaj   +2 more sources

Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population

Scientific Reports, 2021
Prior knowledge of allele frequencies of cytochrome P450 polymorphisms in a population is crucial for the revision and optimization of existing medication choices and doses.
Rattanaporn Sukprasong, Sumonrat Chuwongwattana, Napatrupron Koomdee, Thawinee Jantararoungtong, Santirhat Prommas, Pimonpan Jinda, Jiratha Rachanakul, Nutthan Nuntharadthanaphong, Nutcha Jongjitsook, Apichaya Puangpetch, Chonlaphat Sukasem   +10 more
doaj   +2 more sources

Association between CYP2C19 gene polymorphisms and Helicobacter pylori infection in Hainan region [PDF]

BMC Infectious Diseases
Objective This study was to investigate CYP2C19 gene and their association with H. pylori infection in the region of Hainan. Methods We conducted CYP2C19 genotype analysis in Hainan.
Shimei Huang, Daya Zhang, Da Li, Chen Chen, Fan Zeng, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai   +8 more
doaj   +2 more sources

In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism [PDF]

PeerJ
Background CYP2C19 polymorphisms are correlated with individual variability in response to citalopram treatment. The pharmacogenomic testing of CYP2C19 has been shown to optimize the safety and efficacy of citalopram medication. Exploration of the effect
Peng Wang, Xiao-xia Hu, Jun-wei Li
doaj   +3 more sources

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole

Clinical and Translational Science
Voriconazole is the cornerstone of the treatment and prevention of fungal infections. While there is a good correlation between CYP2C19 genotype and voriconazole exposure during prophylactic treatment, no correlation was found in patients with invasive ...
Sylvia D. Klomp, Anette Veringa, Jan‐Willem C. Alffenaar, Mark G. J. deBoer, Lambert F. R. Span, Henk‐Jan Guchelaar, Jesse J. Swen   +6 more
doaj   +5 more sources

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Clinical pharmacology and therapy, 2022
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition ...
Craig R. Lee, Jasmine A. Luzum, K. Sangkuhl, Roseann S. Gammal, M. Sabatine, C. Stein, D. Kisor, N. Limdi, Yee Ming Lee, S. Scott, J. Hulot, D. Roden, A. Gaedigk, K. Caudle, T. Klein, Julie A. Johnson, A. Shuldiner   +16 more
semanticscholar   +1 more source

Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.

New England Journal of Medicine, 2021
BACKGROUND Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed.
Yongjun Wang, Xia Meng, Anxin Wang, Xuewei Xie, Yuesong Pan, S. Johnston, Hao Li, P. Bath, Q. Dong, Anding Xu, J. Jing, Jinxi Lin, Siying Niu, Yilong Wang, Xingquan Zhao, Zixiao Li, Yong Jiang, Wei Li, Liping Liu, Jie Xu, L. Chang, Lihua Wang, Xianbo Zhuang, Jinguo Zhao, Yefang Feng, Honghao Man, Guozhong Li, Baojun Wang   +27 more
semanticscholar   +1 more source